Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/307% above fair value
$951.19−8.22 (-0.86%)
Close on Nov 12, 2026Market cap $98.40BP/E 21.0Yield –
Regeneron Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Regeneron Pharmaceuticals's cash was $9.30B at Sep 30, 2026. For fiscal 2025 it was $8.61B, down 4.5% from the year before. Over ten years it grew 23.5% a year on average. The highest annual figure on record is $10.84B in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.61B | -4.5% |
| FY2024 | Dec 31, 2024 | $9.01B | -16.9% |
| FY2023 | Dec 31, 2023 | $10.84B | +39.8% |
| FY2022 | Dec 31, 2022 | $7.76B | +35.9% |
| FY2021 | Dec 31, 2021 | $5.71B | +58.5% |
| FY2020 | Dec 31, 2020 | $3.60B | +11.6% |
| FY2019 | Dec 31, 2019 | $3.23B | +14.3% |
| FY2018 | Dec 31, 2018 | $2.82B | +98.5% |
| FY2017 | Dec 31, 2017 | $1.42B | +35.3% |
| FY2016 | Dec 31, 2016 | $1.05B | +0.6% |
| FY2015 | Dec 31, 2015 | $1.05B | +16.1% |
| FY2014 | Dec 31, 2014 | $900.48M | +29.8% |
| FY2013 | Dec 31, 2013 | $693.98M | +125.3% |
| FY2012 | Dec 31, 2012 | $308.10M | -41.5% |
| FY2011 | Dec 31, 2011 | $526.94M | +111.3% |
| FY2010 | Dec 31, 2010 | $249.37M | -26.9% |
| FY2009 | Dec 31, 2009 | $341.33M | +37.7% |
| FY2008 | Dec 31, 2008 | $247.80M | -50.3% |
| FY2007 | Dec 31, 2007 | $498.93M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $9.30B | +10.2% |
| Q2 FY2026 | Jun 30, 2026 | $7.99B | +7.0% |
| Q1 FY2026 | Mar 31, 2026 | $8.75B | +4.8% |
| Q4 FY2025 | Dec 31, 2025 | $8.61B | -4.5% |
| Q3 FY2025 | Sep 30, 2025 | $8.44B | -13.8% |
| Q2 FY2025 | Jun 30, 2025 | $7.47B | -23.8% |
| Q1 FY2025 | Mar 31, 2025 | $8.35B | -20.6% |
| Q4 FY2024 | Dec 31, 2024 | $9.01B | -16.9% |
| Q3 FY2024 | Sep 30, 2024 | $9.80B | -1.2% |
| Q2 FY2024 | Jun 30, 2024 | $9.81B | +9.9% |
| Q1 FY2024 | Mar 31, 2024 | $10.52B | +17.4% |
| Q4 FY2023 | Dec 31, 2023 | $10.84B | +39.8% |
| Q3 FY2023 | Sep 30, 2023 | $9.91B | +41.2% |
| Q2 FY2023 | Jun 30, 2023 | $8.93B | +18.0% |
| Q1 FY2023 | Mar 31, 2023 | $8.96B | +27.1% |
| Q4 FY2022 | Dec 31, 2022 | $7.76B | +35.9% |
| Q3 FY2022 | Sep 30, 2022 | $7.02B | +21.3% |
| Q2 FY2022 | Jun 30, 2022 | $7.57B | +93.5% |
| Q1 FY2022 | Mar 31, 2022 | $7.05B | +101.2% |
| Q4 FY2021 | Dec 31, 2021 | $5.71B | +58.5% |
| Q3 FY2021 | Sep 30, 2021 | $5.79B | +91.3% |
| Q2 FY2021 | Jun 30, 2021 | $3.91B | +24.4% |
| Q1 FY2021 | Mar 31, 2021 | $3.50B | -12.5% |
| Q4 FY2020 | Dec 31, 2020 | $3.60B | +11.6% |
| Q3 FY2020 | Sep 30, 2020 | $3.03B | +5.1% |
| Q2 FY2020 | Jun 30, 2020 | $3.14B | +17.8% |
| Q1 FY2020 | Mar 31, 2020 | $4.00B | +23.9% |
| Q4 FY2019 | Dec 31, 2019 | $3.23B | +14.3% |
| Q3 FY2019 | Sep 30, 2019 | $2.88B | +31.3% |
| Q2 FY2019 | Jun 30, 2019 | $2.67B | +58.6% |
| Q1 FY2019 | Mar 31, 2019 | $3.23B | +98.9% |
| Q4 FY2018 | Dec 31, 2018 | $2.82B | +98.5% |
| Q3 FY2018 | Sep 30, 2018 | $2.19B | +59.0% |
| Q2 FY2018 | Jun 30, 2018 | $1.68B | +32.8% |
| Q1 FY2018 | Mar 31, 2018 | $1.62B | +24.3% |
| Q4 FY2017 | Dec 31, 2017 | $1.42B | +35.3% |
| Q3 FY2017 | Sep 30, 2017 | $1.38B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.27B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.31B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.05B | – |
See a number that looks wrong?